Penn Pharma expands HP manufacturing capabilities in Wales
Penn Pharma has injected £14m ($22m) into its tablet and capsule manufacturing plant in South Wales, UK, in a bid to further its HP offering.
Penn Pharma has injected £14m ($22m) into its tablet and capsule manufacturing plant in South Wales, UK, in a bid to further its HP offering.
The head of Pfizer's virtual clinical trial has defended the project after its initial failure to recruit patients raised questions about its viability.
The US FDA is asking manufacturers to reformulate products containing DBP and DEHP excipients to cut the risk of toxicity.
UPDATE
Horizon Discovery has launched a new website to provide technical support to researchers using its rAAV-mediated genome editing tech.
The EMA wants manufacturers using herbal starting materials to assess the substances’ initial and post-processing contaminant profile.